Company Analysis
Sign in

Arvinas, Inc. (ARVN)

Nasdaq: ARVN · Pharmaceutical Preparations · New Haven, CT · filing with the SEC since 2015
Full chart Alerts Compare
Grade5.7
◀ Past 6.6● Present 6.0▶ Future 4.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$263M-0.3%
Net income-$80.8M+59.4%
Earnings per share$-1.14+58.8%
Operating cash flow-$274M-5.6%
Cash$143M+42.2%
Debt$400,000-33.3%
Shareholders’ equity$434M-22.8%
Shares, diluted70.9M-1.4%
Return on equity-18.6%
The recordfrom its filings
Filings in 202679
Newest filingNov 9 · 4
Annual reportFeb 24, 2026
Quarterly reportNov 3, 2026
Next report due10-K by Mar 16
Insider sales, 12 months$1.4M
Insider buys, 12 months$300,000
Patents granted60
Filer categoryAccelerated filer
Trailing twelve months to Sep 2026Net income -$9.5MCash from operations -$158Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form S-3
Shelf registration
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ARVN · research, not advice